drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (biologic)
drug_description
A humanized IgG1 kappa monoclonal antibody targeting HER2/ErbB2. It binds the HER2 extracellular domain to block receptor dimerization and downstream signaling (e.g., PI3K/AKT, MAPK) and mediates antibody-dependent cellular cytotoxicity (ADCC). In this trial, both Roche’s Herclon and a proposed Incepta biosimilar administer trastuzumab as a single 6 mg/kg IV dose.
nci_thesaurus_concept_id
C1647
nci_thesaurus_preferred_term
Trastuzumab
nci_thesaurus_definition
A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)
drug_mesh_term
Trastuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 monoclonal antibody that binds the HER2/ErbB2 extracellular domain, preventing receptor dimerization and downstream PI3K/AKT and MAPK signaling; promotes receptor downregulation and mediates Fc-dependent ADCC against HER2-overexpressing tumor cells.
drug_name
Trastuzumab
nct_id_drug_ref
NCT06886659